文献速递妇科产科

SMARCA4胚系突变在卵巢高钙血症型小细胞癌与SMARCA4缺陷未分化子宫肉瘤中的临床特征

Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts.
PubMed 文献 · Gynecol Oncol · 2020-01-15

该研究报道了一个携带SMARCA4胚系突变的家族,其中两名成员分别发生卵巢高钙血症型小细胞癌(SCCOHT)和SMARCA4缺陷未分化子宫肉瘤(SMARCA4-DUS),均在诊断后一年内死亡。回顾性比较大型队列显示,SCCOHT患者较SMARCA4-DUS患者更年轻(中位年龄28.5 vs 49.0)且更常见胚系SMARCA4变异(37.5% vs 11.8%)。

要点

  • SCCOHT与SMARCA4-DUS可源于同一家族性SMARCA4胚系突变。
  • SCCOHT患者中位年龄28.5岁,SMARCA4-DUS为49.0岁。
  • SCCOHT胚系SMARCA4变异率37.5%,高于SMARCA4-DUS的11.8%。

核心结论

  • SMARCA4胚系突变家族中可分别发生SCCOHT和SMARCA4-DUS,两例患者均在诊断后一年内死亡。
  • SCCOHT患者比SMARCA4-DUS患者更年轻且胚系SMARCA4变异比例更高。

研究设计与样本

  • 研究提取一个携带胚系SMARCA4突变家族的临床病理病历资料。
  • 从大型CLIA认证参考分子实验室档案中回顾性提取SCCOHT(n=48)和SMARCA4-DUS(n=17)队列的临床基因组数据。

主要发现

  • 该家族两名成员分别发生SCCOHT和SMARCA4-DUS,尽管接受积极手术、化疗和免疫治疗,均在诊断后一年内死亡。
  • SCCOHT患者中位年龄28.5岁,SMARCA4-DUS患者中位年龄49.0岁。
  • SCCOHT患者胚系SMARCA4变异比例为37.5%,SMARCA4-DUS患者为11.8%。

临床怎么用

  • 对SCCOHT和SMARCA4-DUS患者及其家族应考虑SMARCA4胚系检测与遗传咨询。

局限性

  • 家族报告仅涉及单个家族,样本量有限。
  • 队列比较为回顾性分析,来自单一参考分子实验室档案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) and SMARCA4-deficient undifferentiated uterine sarcoma (SMARCA4-DUS) are rare and aggressive tumors, primarily affecting pre- and perimenopausal women. Inactivating SMARCA4 mutations are thought to be the driving molecular events in the majority of these tumors. Here, we report the clinical course of a family with germline SMARCA4 mutation and compare large cohorts of these rare tumor types. METHODS: We extracted clinico-pathological medical record data for the family with germline SMARCA4 mutation. Clinico-genomic data from SCCOHT and SMARCA4-DUS cohorts were retrospectively extracted from the archives of a large CLIA-certified reference molecular laboratory. RESULTS: We identified a single family with an inherited germline SMARCA4 mutation, in which two different family members developed either SCCOHT or SMARCA4-DUS, both of whom died within one year of diagnosis, despite aggressive surgical, chemotherapy and immunotherapy treatment. Retrospective comparative analysis of large SCCOHT (n = 48) and SMARCA4-DUS (n = 17) cohorts revealed that SCCOHT patients were younger (median age: 28.5 vs. 49.0) and more likely to have germline SMARCA4 alterations (37.5% vs. 11.8%) than SMARCA4-DUS patients. CONCLUSIONS: Growing understanding of the role SMARCA4 plays in the pathogenesis of these rare cancers may inform recommended genetic testing and counseling in families with these tumor types.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Connor YD, Miao D, Lin DI, et al. Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts. Gynecol Oncol. 2020. PMID: 31954538. doi:10.1016/j.ygyno.2019.10.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。